Education
About Us
Working with TipRanks
Follow Us
Korro Bio (KRRO)
NASDAQ:KRRO
KRRO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$15.16 - $98.00
Previous CloseN/A
Volume28.02K
Average Volume (3M)94.73K
Market Cap
$163.46M
Enterprise Value$213.93M
Total Cash (Recent Filing)$55.64M
Total Debt (Recent Filing)$44.77M
Price to Earnings (P/E)―
Beta3.98
Next Earnings
May 20, 2025EPS Estimate
-2.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.38
Shares Outstanding9,388,902
10 Day Avg. Volume136,724
30 Day Avg. Volume94,728
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)98.23
Price to Cash Flow (P/CF)-7.40
P/FCF Ratio0.00
Enterprise Value/Market Cap1.31
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit94.20
Enterprise Value/Ebitda-2.33
Forecast
1Y Price Target
$133.00Price Target Upside733.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Korro Bio News
PremiumCompany Announcements
Korro Bio CFO Returns from Medical Leave
PremiumCompany Announcements
Korro Bio Reports 2024 Financial Results and Progress
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe completion of dosing the first two healthy volunteer cohorts may hint at positive safety results for KRRO-110.
Market OpportunitiesThe market-cap difference between KRRO (~$230M) and BEAM (~$2,300M) is seen as an arbitrage opportunity and would be KRRO buyers.
Regulatory AdvantagesKRRO-110 received orphan drug designation from the FDA, which would provide seven years market exclusivity if approved among other advantages.
Bears Say
CompetitionThe opportunity for KRRO-110 in AATD could potentially be similar or superior to BEAM-302, highlighting competition in the market.
Financial PerformanceKorro reported a fourth quarter 2024 net loss of $21.2 million, or $2.38 per share, which beat the consensus estimate of $23.5 million.
Market RisksAbsence of AEs with up to 5mpk LNP dose in NHPs increases confidence in KRRO-110 LNP safety/utilization, which is the main investor pushback.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KRRO FAQ
What was Korro Bio’s price range in the past 12 months?
Korro Bio lowest stock price was $15.16 and its highest was $98.00 in the past 12 months.
What is Korro Bio’s market cap?
Korro Bio’s market cap is $163.46M.
When is Korro Bio’s upcoming earnings report date?
Korro Bio’s upcoming earnings report date is May 20, 2025 which is in 47 days.
How were Korro Bio’s earnings last quarter?
Korro Bio released its earnings results on Mar 18, 2025. The company reported -$2.24 earnings per share for the quarter, beating the consensus estimate of -$2.5 by $0.26.
Is Korro Bio overvalued?
According to Wall Street analysts Korro Bio’s price is currently Undervalued.
Does Korro Bio pay dividends?
Korro Bio does not currently pay dividends.
What is Korro Bio’s EPS estimate?
Korro Bio’s EPS estimate is -2.61.
How many shares outstanding does Korro Bio have?
Korro Bio has 9,388,902 shares outstanding.
What happened to Korro Bio’s price movement after its last earnings report?
Korro Bio reported an EPS of -$2.24 in its last earnings report, beating expectations of -$2.5. Following the earnings report the stock price went down -3.551%.
Which hedge fund is a major shareholder of Korro Bio?
Currently, no hedge funds are holding shares in KRRO
---
Korro Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$133.00 (733.86% Upside)
$133.00 (733.86% Upside)
Hedge Fund Trend
Increased
By 442.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 6.2%
Last 30 Days ▲ 6.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-82.22%
12-Months-Change
Fundamentals
Return on Equity
-50.61%
Trailing 12-Months
Asset Growth
2.06%
Trailing 12-Months
Company Description
Korro Bio
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
---
KRRO Stock 12 Month Forecast
Average Price Target
$133.00
▲(733.86% Upside)
Technical Analysis
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Verve Therapeutics
―
Best Analysts Covering KRRO
1 Year
1 Year Success Rate
1/8 ratings generated profit
1 Year Average Return
-48.34%
reiterated a buy rating 17 days ago
Copying Luca Issi's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -48.34% per trade.
---